Gene therpay for prostate cancer

References

• Greenlee RT, Hill-Harmon MB, Murray T, Thun M. Cancer statistics, 2001. CA Cancerj Clin. 51, 15–36 (2001).
   PubMed Web of Science ®Google Scholar
• Huber PE, Pfisterer P In vitro and in vivo transfection of plasmid DNA in the Dunning prostate tumor R3327-AT1 is enhanced by focused ultrasound. Gene Ther. 7, 1516–1525 (2000).
   PubMed Web of Science ®Google Scholar
• Sun WH, Burkholder JK, Sun J et al In vivo cytokine gene transfer by gene gun reduces tumor growth in mice. Proc. Natl Acad. Sci. USA 92, 2889–2893 (1995)•
   Google Scholar
• Rakhmilevich AL, Turner J, Ford MJ et al. Gene gun-mediated skin transfection with interleukin 12 gene results in regression of established primary and metastatic murine tumors. Proc. Nati Acad. Sci. USA 93, 6291–6296 (1996).
   Google Scholar
• Belldegrun A, Tso CL, Zisman A et aZ Interleukin 2 gene therapy for prostate cancer: Phase I clinical trial and basic biology Hum. Gene Then 12, 883–892(2001).
   Google Scholar
• •First report of Phase I trial of liposome-mediated IL-2 gene therapy for prostate cancer.
   Google Scholar
• Robbins PD, Ghivizzani SC. Viral vectors for gene therapy. Pharmacd Then 80, 35–47 (1998).
   PubMed Web of Science ®Google Scholar
• Logg CR, Tai CK, Logg A, Anderson WE Kasahara N. A uniquely stable replication-competent retrovirus vector achieves efficient gene delivery in vitro and in solid tumors. Hum. Gene Ther. 12, 921–932(2001).
   Google Scholar
• Naldini L, Blomer U, Gallay P et aZ In vivo gene delivery and stable transduction of nondividing cells by a lentiviral vector. Science 272, 263–267 (1996).
   PubMed Web of Science ®Google Scholar
• Podsakoff GM. Lentiviral vectors approach the clinic but fall back: National Institutes of Health Recombinant DNA Advisory Committee review of a first clinical protocol for use of a lentiviral vector. Mot Then 4, 282–283 (2001).
   PubMedGoogle Scholar
• Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Then 8, 628–635 (2001).
   PubMed Web of Science ®Google Scholar
• Rodriguez R Schuur ER, Lim HY, Henderson GA, Simons JW, Henderson DR Prostate attenuated replication competent adenovirus (ARCA) CN706: a selective cytotmdc for prostate-specific antigen-positive prostate cancer cells. Cancer Res. 57, 2559–2563 (1997).
   PubMedGoogle Scholar
• •First report of preclinical studies of replication attenuated adenoviral gene therapy for prostate cancer.
   Google Scholar
• Yu DC, Chen Y, Seng M, Dilley J, Henderson DR The addition of adenovirus Type 5 region E3 enables calydon virus 787 to eliminate distant prostate tumor xenografts. Cancer Res. 59, 4200–4203 (1999).
   PubMed Web of Science ®Google Scholar
• Paielli DL, Wing MS, Rogulski KR et al. Evaluation of the biodistribution, persistence, toxicity and potential of germ-line transmission of a replication-competent human adenovirus following intraprostatic administration in the mouse. MoZ Then 1, 263–274 (2000).
   PubMed Web of Science ®Google Scholar
• •Detailed report of safety of replication-competent adenovirus for prostate cancer gene therapy.
   Google Scholar
• Simons JW A Phase I study of the intraprostatic injections of CN706, a prostate-specific antigen gene-regulated cytolytic adenovirus, in patients with locally recurrent cancer following definitive radiotherapy. Sponsor: Cell Genesys, Inc. www4.ocZnih.gov/ oba/rac/236—(1998–02) (1998).
   Google Scholar
• Freytag SO, Kim JH. Phase I study of intraprostatic administration of a replication-competent, oncolytic adenovirus using various vector formulations to patients with localized prostate cancer prior to radical prostatectomy. Trial# 42842000–10). www4.od.nih.gov/oba/rac/trialquery.asp?C2 = 3dpiid = 5562 (2000).
   Google Scholar
• Miles BJ, Shalev M, Aguilar-Cordova E et al. Prostate-specific antigen response and systemic T cell activation after in situ gene therapy in prostate cancer patients failing radiotherapy. Hum. Gene Then 12, 1955–1967 (2001).
   PubMed Web of Science ®Google Scholar
• ••Results of a Phase I/II clinical trial ofHSV-tk + GCV gene therapy indicated specific biological responses.
   Google Scholar
• Yei S, Mittereder N, Wert S, Whitsett JA, Wilmott RW, Trapnell BC. In vivo evaluation of the safety of adenovirus-mediated transfer of the human cystic fibrosis transmembrane conductance regulator cDNA to the lung. Hum. Gene Then 5, 731–744 (1994).
   PubMed Web of Science ®Google Scholar
• Shalev M, Kadmon D, Teh BS et aZ Suicide gene therapy toxicity after multiple and repeat injections in patients with localized prostate cancer.' UroZ 163, 1747–1750 (2000).
   PubMed Web of Science ®Google Scholar
• Samulski RJ. Adeno-associated virus: integration at a specific chromosomal locus. Curr. Opin. Genet. Dev. 3, 74–80 (1993).
   PubMedGoogle Scholar
• Vieweg J, Boczkowski D, Roberson KM et al. Efficient gene transfer with adeno-associated virus-based plasmids complexed to cationic liposomes for gene therapy of human prostate cancer. Cancer Res. 55, 2366–2372 (1995).
   PubMed Web of Science ®Google Scholar
• Walker JR, Mcgeagh KG, Sundaresan P Jorgensen TJ, Rabkin SD, Martuza RL. T ncAl and systemic therapy of human prostate adenocardnoma with the conditionally replicating herpes simplex virus vector G207. Hum. Gene Ther. 10, 2237–2243 (1999).
   Google Scholar
• Marken JM, Medlock MD, Rabkin SD et al. Conditionally replicating herpes simplex virus mutant, G207 for the treatment of malignant glioma: results of a Phase I trial. Gene Then 7, 867–874 (2000).
   PubMedGoogle Scholar
• Varghese S, Newsome JT, Rabkin SD et al. Preclinical safety evaluation of G207, a replication-competent herpes simplex virus Type 1, inoculated intraprostatically in mice and nonhuman primates. Hum. Gene Then 12, 999–1010 (2001).
   Google Scholar
• Chase M, Chung RY, Chiocca EA. An oncolytic viral mutant that delivers the CYP2B1 transgene and augments cyclophosphamide chemotherapy. Nature Biotechnot 16, 444–448 (1998).
   Google Scholar
• Andreansky S, He B, Van Cott J et al. Treatment of intracranial gliomas in immunocompetent mice using herpes simplex viruses that express murine interleukins. Gene Then 5, 121–130 (1998).
   Google Scholar
• Mukherjee S, Haenel T, Himbeck R et al. Replication-restricted vaccinia as a cytokine gene therapy vector in cancer: persistent transgene expression despite antibody generation. Cancer Gene Then 7, 663–670 (2000).
   PubMed Web of Science ®Google Scholar
• Von Mehren M, Arlen P, Tsang KY et al. Pilot study of a dual gene recombinant avipox vaccine containing both carcinoembryonic antigen (CEA) and B7.1 transgenes in patients with recurrent CEA-expressing adenocarcinomas. Clin. Cancer Res. 6, 2219–2228 (2000).
   Google Scholar
• Eder JP Kantoff PW, Roper K et al. A Phase I trial of a recombinant vaccinia virus expressing prostate-specific antigen in advanced prostate cancer. Clin. Cancer Res. 6, 1632–1638 (2000).
   PubMedGoogle Scholar
• Gnant MF, Puhlmann M, Alexander HR, JR, Bartlett DL. Systemic administration of a recombinant vaccinia virus expressing the cytosine deaminase gene and subsequent treatment with 5-fluorocytosine leads to tumor-specific gene expression and prolongation of survival in mice. Cancer Res. 59, 3396–3403 (1999).
   Google Scholar
• Puhlmann M, Brown CK, Gnant M et al.Vaccinia as a vector for tumor-directed gene therapy: biodistribution of a thymidine kinase-deleted mutant. Cancer Gene Then 7, 66–73 (2000).
   PubMed Web of Science ®Google Scholar
• Kawakita M, Rao GS, Ritchey JK et al. Effect of canarypox virus (ALVAC)-mediated cytokine expression on murine prostate tumor growth. J. Natl Cancer Inst. 89, 428–436 (1997).
   PubMed Web of Science ®Google Scholar
• Martiniello-Wlks R, Garcia-Aragon J, Daja MM et aZ In vivo gene therapy for prostate cancer: preclinical evaluation of two different enzyme-directed prodrug therapy systems delivered by identical adenovirus vectors. Hum. Gene Then 9,1617–1626 (1998).
   PubMedGoogle Scholar
• Rodriguez R, Lim HY, Bartkowski LM, Simons JW Identification of diphtheria toxin via screening as a potent cell cycle and p53-independent cytotoxin for human prostate cancer therapeutics. Prostate 34, 259–269 (1998).
   PubMedGoogle Scholar
• Suzuki S, Tadakuma T, Kunitomi M et al. Liposome-mediated gene therapy using HSV-TK/ganciclovir under the control of human PSA promoter in prostate cancer cells. Ural. Int. 67,216–223 (2001).
   PubMed Web of Science ®Google Scholar
• Yu D, Chen D, Chiu C, Razmazma B, Chow YH, Pang S. Prostate-specific targeting using PSA promoter-based lentiviral vectors. Cancer Gene Then 8, 628–635 (2001).
   PubMed Web of Science ®Google Scholar
• Andriani F, Nan B, Yu J et aZ Use of the probasin promoter ARR2PB to express Box in androgen receptor-positive prostate cancer cells." Natl Cancer Inst. 93,1314-1324 (2001).
   Google Scholar
• Xie X, Zhao X, Liu Yet al. Adenovirus- mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer. Cancer Res. 61,6795-6804 (2001).
   Google Scholar
• Pramudji C, Shirnura S, Ebara S et al. In situ prostate cancer gene therapy using a novel adenoviral vector regulated by the caveolin-1 promoter. Clin. Cancer Res. 7, 4272–4279 (2001).
   Google Scholar
• Thompson T, Timme T, Sehgal I. The role of p53 in prostate cancer progression. In: Accomplishments in Cancer Research. Fortner J, Sharp P (Eds.), Lippincott-Raven Publishers, Philadelphia, PA, USA, 280–289 (1996).
   Google Scholar
• Levine AJ. p53, the cellular gatekeeper for growth and division. Cell 88,323–331 (1997).
   PubMed Web of Science ®Google Scholar
• El-Deiry WS. Regulation of p53 downstream genes. Semin. Cancer Bia 8, 345–357 (1998).
   Google Scholar
• Eastharn JA, Hall SJ, Sehgal I et aZ In vivo gene therapy with p53 or p21 adenovirus for prostate cancer. Cancer Res. 55, 5151–5155 (1995).
   PubMedGoogle Scholar
• •First report of preclinical studies of p53 and p21 gene therapy for prostate cancer.
   Google Scholar
• Yang C, Cirielli C, Capogrossi MC, Passaniti A. Adenovirus-mediated wild-type p53 expression induces apoptosis and suppresses tumorigenesis of prostatic tumor cells. Cancer Res. 55, 4210–4213 (1995).
   PubMed Web of Science ®Google Scholar
• Ko SC, Gotoh A, Thalmann GN et al. Molecular therapy with recombinant p53 adenovirus in an androgen-independent, metastatic human prostate cancer model. Hum. Gene Then 7,1683–1691 (1996).
   Google Scholar
• Gotoh A, Kao C, Ko SC, Hamada K, Liu TJ, Chung LW Cytotoxic effects of recombinant adenovirus p53 and cell cycle regulator genes (p21 WAF1/CIP1 and p16CDKN4) in human prostate cancers.' UroZ 158,636–641 (1997).
   PubMedGoogle Scholar
• Merritt JA, Roth JA, Logothetis CJ. Clinical evaluation of adenoviral-mediated p53 gene transfer: review of INGN 201 studies. Semin. Onca 28,105–114 (2001).
   Google Scholar
• Ittmann MM, Wieczorek R Alterations of the retinoblastoma gene in clinically localized, stage B prostate adenocarcinomas. Hum. Pathot 27,28–34 (1996).
   PubMed Web of Science ®Google Scholar
• Demers GW, Harris MP, Wen SF, Engler H, Nielsen LL, Maneval DC. A recombinant adenoviral vector expressing full-length human retinoblastoma susceptibility gene inhibits human tumor cell growth. Cancer Gene Then 5, 207–214 (1998).
   PubMedGoogle Scholar
• Xu HJ, Zhou Y, Seigne J et al. Enhanced tumor suppressor gene therapy via replication-deficient adenovirus vectors expressing an N-terminal truncated retinoblastoma protein. Cancer Res. 56, 2245–2249 (1996).
   PubMed Web of Science ®Google Scholar
• Harper JW Cyclin dependent kinase inhibitors. Cancer Surv. 29, 91–107 (1997).
   Google Scholar
• Wang TJ, Huang MS, Hong CY, Tse V, Silverberg GD, Hsiao M. Comparisons of tumor suppressor p53, p21 and p16 gene therapy effects on glioblastoma tumorigenicity in situ. Biochem. Biophys. Res. Commun. 287,173-180 (2001).
   Google Scholar
• Serrano M, Hannon GJ, Beach D. A new regulatory motif in cell-cycle control causing specific inhibition of cyclin D/CDK4. Nature 366,704–707 (1993).
   Google Scholar
• Jarrard DF, Bova GS, Ewing CM et aZ Deletional, mutational and methylation analyses of CDKN2 (p16/MTS1) in primary and metastatic prostate cancer. Genes Chromosomes Cancer 19,90–96 (1997).
   PubMed Web of Science ®Google Scholar
• Allay JA, Steiner MS, Zhang Y, Reed CP, Cockroft J, Lu Y. Adenovirus p16 gene therapy for prostate cancer. World J. UroZ 18, 111–120 (2000).
   Google Scholar
• Steiner MS, Zhang Y, Farooq F, Lerner J, Wang Y, Lu Y. Adenoviral vector containing wild-type p16 suppresses prostate cancer growth and prolongs survival by inducing cell senescence. Cancer Gene Then 7, 360–372 (2000).
   PubMed Web of Science ®Google Scholar
• Syrigos KN, Harrington KJ, Pignatelli M. Role of adhesion molecules in bladder cancer, an important part of the jigsaw. Urology 53,428–434 (1999).
   Google Scholar
• Lin SH, Pu YS. Function and therapeutic implication of C-CAM cell-adhesion molecule in prostate cancer. Semin.Onca 26, 227–233 (1999).
   PubMedGoogle Scholar
• Lin SH, Pu YS, Luo W, Wang Y, Logothetis CJ. Schedule-dependence of C-CAM1 adenovirus gene therapy in a prostate cancer model. Anticancer Res. 19, 337–340 (1999).
   Google Scholar
• Steiner MS, Zhang X, Wang Y, Lu Y. Growth inhibition of prostate cancer by an adenovirus expressing a novel tumor suppressor gene, pHyde. Cancer Res. (2000) 60,4419–4425.
   PubMed Web of Science ®Google Scholar
• Zhou BB, Elledge SJ. The DNA damage response: putting checkpoints in perspective. Nature 408,433–439 (2000).
   PubMed Web of Science ®Google Scholar
• Rosen EM, Fan S, Goldberg ID. BRCA1 and prostate cancer. Cancer Invest. 19,396-412 (2001).
   Google Scholar
• Tait DL, Obermiller PS, Hatmaker AR, Redlin-Frazier S, Holt JT. Ovarian cancer BRCA1 gene therapy: Phase I and II trial differences in immune response and vector stability. Clin. Cancer Res. 5, 1708–1714 (1999).
   Google Scholar
• Mcdonnell TJ, Troncoso P, Brisbay SM et al. Expression of the protooncogene bc1-2 in the prostate and its association with emergence of androgen-independent prostate cancer. Cancer Res. 52,6940–6944 (1992).
   PubMed Web of Science ®Google Scholar
• Adams JM, Cory S. The Bc1-2 protein family, arbiters of cell survival. Science 281, 1322–1326 (1998).
   PubMed Web of Science ®Google Scholar
• Dorai T, Olsson CA, Katz AE, Buttyan R Development of a hammerhead ribozyme against bc1-2. I. Preliminary evaluation of a potential gene therapeutic agent for hormone-refractory human prostate cancer. Prostate 32,246–258 (1997).
   Google Scholar
• Benimetskaya L, Miller P, Benimetsky S et aZ Inhibition of potentially anti-apoptotic proteins by antisense protein kinase C-a (Isis 3521) and antisense bc1-2 (G3139) phosphorothioate oligodeoxynucleotides: relationship to the decreased viability of T24 bladder and PC3 prostate cancer cells. Mot Pharmacot 60, 1296–1307 (2001).
   PubMed Web of Science ®Google Scholar
• Geiger T, Muller M, Monia BP, Fabbro D. Antitumor activity of a C-raf antisense oligonucleotide in combination with standard chemotherapeutic agents against various human tumors transplanted subcutaneously into nude mice. (lin. Cancer Res. 3, 1179–1185 (1997).
   Google Scholar
• Balaji KC, Koul H, Mitra S et at Antiproliferative effects of c-myc antisense oligonucleotide in prostate cancer cells: a novel therapy in prostate cancer. Urology 50, 1007–1015 (1997).
   PubMed Web of Science ®Google Scholar
• Steiner MS, Anthony Cr, Lu Y, Holt JT. Antisense c-myc retroviral vector suppresses established human prostate cancer. Hum. Gene Then 9, 747–755 (1998).
   PubMed Web of Science ®Google Scholar
• Shariat SF, Desai S, Song Wet aZ Adenovirus-mediated transfer of inducible caspases: a novel 'death switch' gene therapeutic approach to prostate cancer. Cancer Res. 61, 2562–2571 (2001).
   PubMed Web of Science ®Google Scholar
• Marcelli M, Cunningham GR, Walkup M et aZ Signaling pathway activated during apoptosis of the prostate cancer cell line LNCaP: overexpression of caspase-7 as a new gene therapy strategy for prostate cancer. Cancer Res. 59, 382–390 (1999).
   PubMed Web of Science ®Google Scholar
• Li X, Marani M, Yu J et id Adenovirus- mediated Box overexpression for the induction of therapeutic apoptosis in prostate cancer. Cancer Res. 61, 186–191 (2001).
   PubMed Web of Science ®Google Scholar
• Bateman A, Bullough F, Murphy S et aZ Fusogenic membrane glycoproteins as a novel class of genes for the local, immune-mediated control of tumor growth. Cancer Res. 60, 1492–1497 (2000).
   PubMed Web of Science ®Google Scholar
• Higuchi H, Bronk SF, Bateman A, Harrington K, Vile RG, Gores GJ. Viral fusogenic membrane glycoprotein expression muses syncytia formation with bioenergetic cell death: implications for gene therapy. Cancer Res. 60, 6396–6402 (2000).
   PubMedGoogle Scholar
• Galanis E, Bateman A, Johnson K et aZ Use of viral fusogenic membrane glycoproteins as novel therapeutic transgenes in gliomas. Hum. Gene Then 12, 811–821 (2001).
   PubMed Web of Science ®Google Scholar
• Springer CJ, Niculescu-Duvaz I. Prodrug- activating systems in suicide gene therapy.' Clin. Invest. 105, 1161–1167(2000).
   Google Scholar
• Huber BE, Austin EA, Richards CA, Davis ST, Good SS. Metabolism of 5-fluorocytosine to 5-fluorouracil in human colorectal tumor cells transduced with the cytosine deaminase gene: significant antitumor effects when only a small percentage of tumor cells express cytosine deaminase. Proc. Natl Acad. Sci. USA 91, 8302–8306 (1994).
   Google Scholar
• Eastham JA, Chen SH, Sehgal I et aZ Prostate cancer gene therapy: herpes simplex virus thymidine kinase gene transduction followed by ganciclovir in mouse and human prostate cancer models. Hum. Gene Then 7, 515–523 (1996).
   PubMed Web of Science ®Google Scholar
• •First report of preclinical studies of HSV-tk + GCV gene therapy for prostate cancer.
   Google Scholar
• Hall SJ, Mutchnik SE, Chen SH, Woo SL, Thompson TC. Adenovirus-mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy leads to systemic activity against spontaneous and induced metastasis in an orthotopic mouse model of prostate cancer. Int. J. Cancer 70, 183–187(1997).
   Google Scholar
• Hall SJ, Mutchnik SE, Yang G et at Cooperative therapeutic effects of androgen ablation and adenovirus- mediated herpes simplex virus thymidine kinase gene and ganciclovir therapy in experimental prostate cancer. Cancer Gene Then 6, 54–63 (1999).
   PubMed Web of Science ®Google Scholar
• Cheon J, Kim HK, Moon DG, Yoon DK, Cho JH, Koh SK. Adenovirus-mediated suicide-gene therapy using the herpes simplex virus thymidine kinase gene in cell and animal models of human prostate cancer: changes in tumour cell proliferative activity. BJU Int. 85, 759–766 (2000).
   PubMed Web of Science ®Google Scholar
• Herman JR, Adler HL, Aguilar-Cordova E et al. In situ gene therapy for adenocarcinoma of the prostate: a Phase I clinical trial. Hum. Gene Then 10, 1239–1249 (1999).
   PubMed Web of Science ®Google Scholar
• •Report of Phase I trial of HSV-tk + GCV gene therapy for prostate cancer.
   Google Scholar
• Rainov NG, Kramm CM, Banning U et al. Immune response induced by retrovirus-mediated HSV-tk/GCV pharmacogene therapy in patients with glioblastoma multiforme. Gene Then 7, 1853–1858 (2000).
   PubMed Web of Science ®Google Scholar
• Ayala G, Wheeler TM, Shalev M et al. Cytopathic effect of in situ gene therapy in prostate cancer. Hum. PathoZ 31, 866–870 (2000).
   PubMed Web of Science ®Google Scholar
• Atkinson G, Hall SJ. Prodrug activation gene therapy, external beam irradiation in the treatment of prostate cancer. Urology 54, 1098–1104 (1999).
   PubMed Web of Science ®Google Scholar
• Chikara M, Huang H, Vlachaki MT et al. Enhanced therapeutic effect of HSV-tk+GCV gene therapy, ionizing radiation for prostate cancer. Mot Then 3, 536–542 (2001).
   PubMedGoogle Scholar
• Nasu Y, Bangma C, Hull G et at Combination gene therapy with adenoviral vector-mediated HSV-tk+GCV and IL-12 in an orthotopic mouse model for prostate cancer. Prostate Cancer Prostatic Diseases 4, 44 55 (2001).
   PubMedGoogle Scholar
• Koeneman KS, Kao C, Ko SC et aZ Osteocakin-directed gene therapy for prostate-cancer bone metastasis. World 1. Ural. 18, 102–110 (2000).
   Google Scholar
• Chung LWK, Gardner TA. Phase I study of Ad-OGTK plus valacyclovir for the treatment of metastatic or recurrent prostate cancer. wzvw4.od.nih.gov/oba/rac/ Trial #276-(1998–12) (1998).
   Google Scholar
• Freytag SO, Rogulski KR, Paielli DL, Gilbert JD, Kim JH. A novel three-pronged approach to kill cancer cells selectively: concomitant viral, double suicide gene and radiotherapy. Hum. Gene Then 9, 1323–1333 (1998).
   Google Scholar
• •Report of preclinical studies of combined gene therapy for prostate cancer.
   Google Scholar
• Anello R, Cohen S, Atkinson G, Hall SJ. Adenovirus mediated cytosine deaminase gene transduction and 5-fluorocytosine therapy sensitizes mouse prostate cancer cells to irradiation.' Ural. 164, 2173–2177 (2000).
   PubMedGoogle Scholar
• Rogulski KR, Kim JH, Kim SH, Freytag SO. Glioma cells transduced with an Escherichia coli CD/HSV-1 TK fusion gene exhibit enhanced metabolic suicide and radiosensitivity. Hum. Gene Then 8, 73–85 (1997).
   Google Scholar
• Blackburn RV, Galoforo SS, Corry PM, Lee YJ. Adenoviral transduction of a cytosine deaminase/thymidine kinase fusion gene into prostate carcinoma cells enhances prodrug and radiation sensitivity. Int. J. Cancer 82, 293–297 (1999).
   PubMed Web of Science ®Google Scholar
• Nasu Y Bangma CH, Hull GW et aZ Adenovirus-mediated interleukin-12 gene therapy for prostate cancer: suppression of orthotopic tumor growth and pre-established lung metastows in an orthotopic model. Gene Then 6, 338–349 (1999).
   PubMedGoogle Scholar
• •First report of preclinical studies of immunomodulatory gene therapy for prostate cancer.
   Google Scholar
• Suzuki K, Nakazato H, Matsui H et aZ NK cell-mediated anti-tumor immune response to human prostate cancer cell, PC-3: irnmunogene therapy using a highly secreTable form of interleukin-15 gene transfer.j Leukoc. Bid 69, 531–537 (2001).
   Google Scholar
• Hull GW, McCurdy MA, Nasu Yet al. Prostate cancer gene therapy: comparison of adenovirus-mediated expression of interleukin 12 with interleukin 12 plus B7-1 for in situ gene therapy and gene-modified, cell-based vaccines. Clin. Cancer Res. 6, 4101–4109 (2000).
   Google Scholar
• Chen L, Ashe S, Brady WA et at Gostimulation of antitumor immunity by the B7 counterreceptor for the T lymphocyte molecules CD28 and CTLA-4. Ce1171, 1093–1102 (1992).
   Google Scholar
• Sanda MG, Ayyagari SR, Jaffee EM et al. Demonstration of a rational strategy for human prostate cancer gene therapy. J. Urd 151, 622–628 (1994).
   PubMed Web of Science ®Google Scholar
• Simons JW, Mikhak B, Chang JF et d Induction of immunity to prostate cancer antigens: results of a clinical trial of vaccination with irradiated autologous prostate tumor cells engineered to secrete granulocyte-macrophage colony-stimulating factor using ex vivo gene transfer. Cancer Res. 59, 5160–5168 (1999).
   PubMed Web of Science ®Google Scholar
• •First report of clinical trial of vaccination for prostate cancer with ex vivo modified tumor cells.
   Google Scholar